全体基調パネルディスカッション

1月22日(水) | 1:45 - 3:05 pm

革新の時代における研究開発の課題

The PepTalk Plenary Keynote Panel convenes a group of leading scientists working across novel therapeutic modalities and R&D technologies to explore the many challenges associated with discovering, developing, and advancing today’s novel biotherapeutics. The Panel, via a highly interactive format, encourages discussion among both the panelists and the audience members. Please come prepared with your questions and ideas for this spirited discussion.

 

  • Advances and challenges in expression and production for novel modalities
  • Implementing next-generation informatics: data collection, standardization, analysis, ML/AI, and considerations for IP landscape and protection
  • Implementing R&D and production capacity for gene and cell therapies – where are we heading?
  • Modality-specific challenges: multi-specifics for cancer, improving the ADC therapeutic window, improved safety and pharmacology, novel delivery/targeting
  • Preclinical and clinical development of drug combinations with focus in IO: How do we select the right combination dose so we can accelerate clinical development?

Moderator:

Mohammad Tabrizi, PhD, Senior Director, Pharmacology, Ascendis Pharma A/S


Panelists:

Vijay Chiruvolu, PhD, Senior Vice President of Global Process Development - Cell Therapy, Kite Pharma, a Gilead Sciences Company


Edward Kraft, PhD, Senior Scientific Manager, Biomolecular Resources, Genentech


David E. Szymkowski, PhD, Vice President, Cell Biology, Xencor, Inc.


Alayna George Thompson, PhD, Senior Scientist I, Drug Discovery Science & Technology, AbbVie



Additional Conference Keynote Speakers

Paolo Arosio, PhD, Professor, Biochemical Engineering, Department of Chemistry and Applied Biosciences, ETH Zurich


Phillip Berman, PhD, Distinguished Research Professor, Biomolecular Engineering, University of California, Santa Cruz


Murali Bilikallahalli, PhD, Vice President and Head of Technical Operations, Acceleron Pharma


Bryan Briney, PhD, Assistant Professor, Immunology and Microbiology, The Scripps Research Institute


Partha S. Chowdhury, Senior Director, Biologics Research, Sanofi Genzyme


Rakesh Dixit, PhD, DABT, President & CEO, Bionavigen, LLC


Aris N. Economides, PhD, Vice President, Research, Regeneron Pharmaceuticals, Inc.


Guangping Gao, PhD, Co-Director, Li Weibo Institute for Rare Diseases Research; Director, Horae Gene Therapy Center and Viral Vector Core; Professor, Microbiology and Physiological Systems, University of Massachusetts Medical School


Mo Heidaran, PhD, Vice President, Technical, PAREXEL Consulting, PAREXEL International


Alois Jungbauer, PhD, Professor and Head, Institute of Bioprocess Science and Engineering, Biotechnology, University of Natural Resources and Life Sciences (BOKU)


John K. Kawooya, PhD, Director, Biologics Optimization, Discovery Research, Amgen, Inc.


Josh LaBaer, MD, PhD, Executive Director, Biodesign Institute, Arizona State University


Muthiah (Mano) Manoharan, PhD, Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals, Inc.


Shahram Salek-Ardakani, PhD, Senior Director, Cancer Immunology Discovery, Pfizer


Peter Schurtenberger, PhD, Professor, Department of Chemistry, Lund University


Peter M. Tessier, PhD, Professor, Pharmaceutical Sciences, Chemical Engineering and Biomedical Engineering, University of Michigan


Elizabeth M. Topp, PhD, Dane O. Kildsig Chair and Department Head, Department of Industrial and Physical Pharmacy, Purdue University


Cenk Undey, PhD, Executive Director, Process Development, Amgen


Renaud Vincentelli, PhD, Head, High-Throughput Protein Production, Structural Biology Core, Architecture et Fonction des Macromolécules Biologiques (AFMB), UMR, CNRS – Aix-Marseille University


Gerhard Winter, PhD, Professor, Chair, Pharmaceutical Technology and Biopharmaceutics, LMU Munchen

 

 

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English


更新通知サービス
更新履歴
2019/09/25
アジェンダ・スポンサー更新
2019/08/23
スポンサー更新




2020年のカンファレンスプログラムと研修セミナー


メール配信サービス